Navigation Links
Tumor blood vessels prevent the spread of cancer cells
Date:2/11/2013

A lack of the protein endoglin in the blood vessels of tumour-bearing mice enables the spread of daughter tumours, according to researchers at Karolinska Institutet and Lund University in Sweden in a study published in the scientific periodical The Journal of Experimental Medicine. Given that the tumour vasculature constitutes an important barrier to the spread of cancer cells, the team suggests that drugs should be developed to strengthen the blood vessels' protective function.

Studies of the process of metastasis (the spread of daughter tumours) have mainly focused on how the properties of the cancer cells themselves promote their spread. For the present study, however, the researchers studied the function of a specific signal pathway consisting of the protein endoglin in the vasculature of tumour-bearing mice. They discovered that when the gene that codes for endoglin was missing in the blood vessels in tumours in the breast, lung or pancreas, it led to increased metastatic spread to other organs.

"The study shows that the blood vessels play an important role in preventing the spread of tumour cells through the blood stream," says Kristian Pietras, professor at Lund University and also affiliated to Karolinska Institutet. "This is because blood vessels lacking in endoglin change in a way that makes it easier for the cancer cells to enter the blood stream and spread to other organs. So with this in mind, we suggest that drugs should be developed to strengthen the barrier function of the blood vessels to prevent the spread of cancer."

The results of the study are also of significance to patients with the rare congenital syndrome Hereditary Hemorrhagic Telangiectasia (HHT), which in some patients is caused by the lack of onecopy of the endoglin gene. HHT causes deformities of the blood capillaries and increases the risk of haemorrhage. The researchers believe that HHT patients afflicted by cancer should be monitored particularly closely since their vascular barrier against metastatic spread might be defective.

"At the same time, we also show that tumours that have developed in mice lacking the endoglin gene are considerably more sensitive to treatment with a certain kind of antiangiogenic drugs that target the growth factor VEGF," says Professor Pietras. "HHT patients with cancer may therefore benefit greatly from the VEGF blockers currently in clinical use."

"Going by the results of our study, we also suggest, paradoxically, that a combination of drugs that block endoglin and VEGF should be tried as an effective cancer therapy; a solution thatis already being tested in clinical studies in the USA," he adds.


'/>"/>

Contact: Karolinska Institutet Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert

Related biology news :

1. The loss of a protein makes jump the tumor to the lymph node
2. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
3. Dental X-rays linked to common brain tumor
4. TGen leads new National Institutes of Health study of brain tumors
5. Immune-response genes affecting breast tumor eradication
6. A single stem cell mutation triggers fibroid tumors
7. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
8. Cancerous tumors deliver pro-metastatic information in secreted vesicles
9. Researchers identify need to sample multiple tumor zones in breast cancer
10. Tumor microenvironment helps skin cancer cells resist drug treatment
11. BGI debuts new tool PDXomics for tumor xenograft research and applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology: